Company news

Atea Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

May 6, 2024

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

April 28, 2024

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

March 26, 2024

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

February 27, 2024

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

February 20, 2024

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

January 7, 2024

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

November 12, 2023

Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences

November 7, 2023

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023

October 31, 2023

Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

July 31, 2023

Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination

June 14, 2023

Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences

May 29, 2023

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 7, 2023

Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023

April 30, 2023

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19

April 24, 2023

Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases

April 11, 2023

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 27, 2023

Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023

February 22, 2023

Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023

February 20, 2023

Atea Pharmaceuticals Highlights Strategic Priorities for 2023

January 8, 2023

Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19

November 28, 2022

Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

November 6, 2022

Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

November 2, 2022

Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022

October 30, 2022

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue

September 25, 2022

Atea Pharmaceuticals Announces Upcoming Investor Events

September 6, 2022

Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 7, 2022

Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022

July 31, 2022

Atea Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call on May 10, 2022

May 2, 2022

Atea Pharmaceuticals Reports Nonclinical Bemnifosbuvir (AT-527) Toxicology Data at Society of Toxicology 61st Annual Meeting

March 27, 2022

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 27, 2022

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

February 9, 2022

Atea Pharmaceuticals Announces Publication of Data Supporting Bemnifosbuvir’s (AT-527) Novel Mechanism of Action Against SARS-CoV-2 in Nature Communications

February 1, 2022

Atea Pharmaceuticals Highlights Strategic Priorities for 2022

January 6, 2022

Atea Pharmaceuticals Introduces New Strategic Clinical Development Program for AT-527 in COVID-19

December 13, 2021

Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche

November 15, 2021

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results

November 10, 2021

Atea Pharmaceuticals to Host Third Quarter Financial Results Conference Call on November 11, 2021

November 3, 2021

Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting

October 18, 2021

Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses

August 23, 2021

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results

August 11, 2021

Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche

June 15, 2021

Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs

June 14, 2021

Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of Directors

May 19, 2021

Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 12, 2021

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

April 28, 2021

Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

March 29, 2021

Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections

March 5, 2021

Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan

February 18, 2021

Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

February 7, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.